MedWatch

BioPorto CEO announces new strategy

It is a commercial Mr. Turnaround, who now sits at the helm of Danish pharma company, BioPorto. After one day on the job, Peter Mørch Eriksen has already outlined a plan for how the company is to move forward.

Foto: Oscar Urrutia

Peter Mørch Eriksen has two successful turnarounds on his CV - in the 90s for technology firm Brüel & Kjær, while the diagnostic division in Medtronic came under the care of the commercial expert later on. Now the time has come for BioPorto to make use of his expertise. Peter Mørch Eriksen has already decided on the overall steps for advancement of the distressed diagnostics company.

“I believe we have to reach out to more doctors. BioPorto is represented in 80 countries, and the 80-20 rule applies in this case as well, I suppose. We have to focus our efforts on specific markets, and we have to be a lot more focused on a gradual approach to our growth, instead of spreading it out,” Peter Mørch Eriksen explains.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Eli Lilly får forlomme til fedmehåb hos FDA

Med en fast track status får medicinalselskabet Eli Lilly sænket behandlingstiden for sin registreringsansøgning hos FDA af lægemiddelhåbet Tirzepatid til omtrent seks måneder fra de normale ca. 10 måneder.

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier